RxDoctor Payments Data

Ruby Kassanoff, MD

Internal Medicine · Dallas, TXNPI 1467464594

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 111 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$232
  • AbbVie$219
  • Amarin Pharma, Inc.$215
  • Amgen$201
  • Abbott$176
  • Astellas Pharma US Inc$111
  • plus $723 from 23 others

What the payments were for

  • Food & beverage$1,85899%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,876 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$110,308
Medicare patients
189
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$71,449
OzempicSemaglutide27$25,672
MyrbetriqMirabegron28$16,986
Praluent PenAlirocumab20$16,191
XareltoRivaroxaban21$15,987
JanuviaSitagliptin Phosphate13$12,708
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$8,342
SynthroidLevothyroxine Sodium112$7,905
Repatha SureclickEvolocumab13$6,779
Rosuvastatin Calcium273$6,341
EntrestoSacubitril/Valsartan11$6,248
Spiriva RespimatTiotropium Bromide11$5,853
PremarinEstrogens, Conjugated15$4,729
PaxlovidNirmatrelvir/Ritonavir39$4,287
Incruse ElliptaUmeclidinium Bromide13$3,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$45$80,465147 claims
Novo NordiskOzempic$232$25,67227 claims
Astellas Pharma US IncMyrbetriq$111$16,98628 claims
Johnson & JohnsonXarelto$54$15,98721 claims
MerckJanuvia$13$12,70813 claims
AbbVieSynthroid$219$7,905112 claims
Boehringer IngelheimSpiriva Respimat$36$5,85311 claims
GSKIncruse Ellipta$80$3,86913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →